NeoPhore Announces Scientific Founder Dr Alberto Bardelli Awarded €2.5 million European Research Council (ERC) Advanced Grant

22 April, Cambridge, UK – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announced that its scientific founder, Dr Alberto Bardelli Department of Oncology, University of Turin, has been awarded an ERC Advanced Grant of €2.5 million for a 5 year programme ‘Targeting DNA repair pathways, sparking anti-cancer immunity’.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...